Nanjing Zenkom Pharmaceutical Co., Ltd.

Primary objective: To investigate the pharmacokinetic characteristics of a single oral dose of the test formulation merogabarine besylate tablets (5 mg, manufactured by Nanjing Zhengke Pharmaceutical Co., Ltd.) and the reference formulation merogabarine besylate tablets (trade name: Delijing®, 5 mg, licensee: DAIICHI SANKYO CO., LTD.) in healthy participants under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations in humans. Secondary objective: To observe the safety of the test formulation merogabarine besylate tablets and the reference formulation (Delijing®) in healthy participants.

This study used eletrogliflozin tablets manufactured by Nanjing Zhengke Pharmaceutical Co., Ltd. as the test formulation (T), and eletrogliflozin tablets (trade name: STEGLATRO®/Jianuotu®) manufactured by Pfizer Manufacturing Deutschland GmbH as the reference formulation (R). The aim was to evaluate the bioavailability of the test and reference formulations in healthy participants after a single oral dose in a fasting state, and to assess the bioequivalence of the two formulations. Secondary objective: To evaluate the safety of the test and reference formulations in healthy participants.

Primary objective: Using baricitinib tablets produced by Nanjing Zhengke Pharmaceutical Co., Ltd. as the test preparation (T), and baricitinib tablets (trade name: OLUMIANT®) certified by Eli Lilly Nederland B.V. as the reference preparation (R), evaluate the pharmacokinetic characteristics of the test preparation and the reference preparation after a single oral administration in healthy subjects in the fasting and postprandial state, and evaluate the bioequivalence of the two preparations. Secondary objective: Evaluate the safety of the test preparation and the reference preparation in healthy subjects.